Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
GSK PLC Sponsored ADR (GSK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK PLC Sponsored ADR (GSK) - free report >>
Here's Why Moderna (MRNA) Stock is Jumping Today
On Monday, shares of biotech Moderna Inc. (MRNA - Free Report) soared over 26% in midday trading, and closed up nearly 20% to $80 a share.
Investors were bullish on positive results from a Phase 1 study of Moderna’s coronavirus vaccine candidate. The company tested three different dosing regimens in healthy adults aged 18-55, and participants in all three groups developed antibodies against COVID-19 by day 15 after dosing.
Antibodies could be a strong indicator of immunity.
Moderna said the vaccine appears to be generally safe and well tolerated.
Going forward, Moderna expects a Phase 2 study to begin soon, and a Phase 3 test is set for July.
In other coronavirus new, Vir Biotechnology (VIR - Free Report) also announced today that it selected two potential coronavirus treatments, which will now be sent into clinical testing with GlaxoSmithKline (GSK - Free Report) .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>